Expert Interview
Discussing the potential of uniQure's gene therapy AMT-130 and PTC Therapeutics candidate PTC518 in Huntington's Disease.
Ticker(s): QURE, PTCTInstitution: Mount Sinai
- Board certified Neurologist and movement disorders specialist
- Treats 45 patients with Huntington's disease
- Manages 1200 patients for Parkinson's disease
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
